64 related articles for article (PubMed ID: 31324883)
1. Forkhead domain mutations in FOXA1 drive prostate cancer progression.
Gao S; Chen S; Han D; Barrett D; Han W; Ahmed M; Patalano S; Macoska JA; He HH; Cai C
Cell Res; 2019 Sep; 29(9):770-772. PubMed ID: 31324883
[No Abstract] [Full Text] [Related]
2. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.
Baca SC; Takeda DY; Seo JH; Hwang J; Ku SY; Arafeh R; Arnoff T; Agarwal S; Bell C; O'Connor E; Qiu X; Alaiwi SA; Corona RI; Fonseca MAS; Giambartolomei C; Cejas P; Lim K; He M; Sheahan A; Nassar A; Berchuck JE; Brown L; Nguyen HM; Coleman IM; Kaipainen A; De Sarkar N; Nelson PS; Morrissey C; Korthauer K; Pomerantz MM; Ellis L; Pasaniuc B; Lawrenson K; Kelly K; Zoubeidi A; Hahn WC; Beltran H; Long HW; Brown M; Corey E; Freedman ML
Nat Commun; 2021 Mar; 12(1):1979. PubMed ID: 33785741
[TBL] [Abstract][Full Text] [Related]
3. The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis.
Pomerantz MM; Li F; Takeda DY; Lenci R; Chonkar A; Chabot M; Cejas P; Vazquez F; Cook J; Shivdasani RA; Bowden M; Lis R; Hahn WC; Kantoff PW; Brown M; Loda M; Long HW; Freedman ML
Nat Genet; 2015 Nov; 47(11):1346-51. PubMed ID: 26457646
[TBL] [Abstract][Full Text] [Related]
4. FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer.
Wang Z; Townley SL; Zhang S; Liu M; Li M; Labaf M; Patalano S; Venkataramani K; Siegfried KR; Macoska JA; Han D; Gao S; Risbridger GP; Taylor RA; Lawrence MG; He HH; Selth LA; Cai C
Nat Commun; 2024 Jun; 15(1):4914. PubMed ID: 38851846
[TBL] [Abstract][Full Text] [Related]
5. Clinically-observed FOXA1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer.
Tam KJ; Liu L; Hsing M; Dalal K; Thaper D; McConeghy B; Yenki P; Bhasin S; Peacock JW; Wang Y; Cherkasov A; Rennie PS; Gleave ME; Ong CJ
Sci Rep; 2024 Mar; 14(1):7082. PubMed ID: 38528115
[TBL] [Abstract][Full Text] [Related]
6. Parallel Reporter Assays Identify Altered Regulatory Role of rs684232 in Leading to Prostate Cancer Predisposition.
Ren N; Liu Q; Yan L; Huang Q
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445492
[TBL] [Abstract][Full Text] [Related]
7. High clonal diversity and spatial genetic admixture in early prostate cancer and surrounding normal tissue.
Zhang N; Harbers L; Simonetti M; Diekmann C; Verron Q; Berrino E; Bellomo SE; Longo GMC; Ratz M; Schultz N; Tarish F; Su P; Han B; Wang W; Onorato S; Grassini D; Ballarino R; Giordano S; Yang Q; Sapino A; Frisén J; Alkass K; Druid H; Roukos V; Helleday T; Marchiò C; Bienko M; Crosetto N
Nat Commun; 2024 Apr; 15(1):3475. PubMed ID: 38658552
[TBL] [Abstract][Full Text] [Related]
8. FOXA1 and FOXA2: the regulatory mechanisms and therapeutic implications in cancer.
Liu N; Wang A; Xue M; Zhu X; Liu Y; Chen M
Cell Death Discov; 2024 Apr; 10(1):172. PubMed ID: 38605023
[TBL] [Abstract][Full Text] [Related]
9. Atypical inflammatory kinase IKBKE phosphorylates and inactivates FoxA1 to promote liver tumorigenesis.
Gao B; Wu X; Bu L; Jiang Q; Wang L; Liu H; Zhang X; Wu Y; Li X; Li J; Liang Y; Xu L; Xie W; Guo J
Sci Adv; 2024 Feb; 10(6):eadk2285. PubMed ID: 38324694
[TBL] [Abstract][Full Text] [Related]
10. Unveiling the Molecular Landscape of
Hwang KW; Yun JW; Kim HS
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958805
[TBL] [Abstract][Full Text] [Related]
11. SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1.
Wang Z; Petricca J; Liu M; Zhang S; Chen S; Li M; Besschetnova A; Patalano S; Venkataramani K; Siegfried KR; Macoska JA; Han D; Gao S; Vedadi M; Arrowsmith CH; He HH; Cai C
Proc Natl Acad Sci U S A; 2023 Aug; 120(33):e2220472120. PubMed ID: 37549269
[TBL] [Abstract][Full Text] [Related]
12. Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer.
Li X; Wang Y; Deng S; Zhu G; Wang C; Johnson NA; Zhang Z; Tirado CR; Xu Y; Metang LA; Gonzalez J; Mukherji A; Ye J; Yang Y; Peng W; Tang Y; Hofstad M; Xie Z; Yoon H; Chen L; Liu X; Chen S; Zhu H; Strand D; Liang H; Raj G; He HH; Mendell JT; Li B; Wang T; Mu P
Cancer Cell; 2023 Aug; 41(8):1427-1449.e12. PubMed ID: 37478850
[TBL] [Abstract][Full Text] [Related]
13. LSD1 Inhibition Disrupts Super-Enhancer-Driven Oncogenic Transcriptional Programs in Castration-Resistant Prostate Cancer.
Li M; Liu M; Han W; Wang Z; Han D; Patalano S; Macoska JA; Balk SP; He HH; Corey E; Gao S; Cai C
Cancer Res; 2023 May; 83(10):1684-1698. PubMed ID: 36877164
[TBL] [Abstract][Full Text] [Related]
14. Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential.
Kneppers J; Severson TM; Siefert JC; Schol P; Joosten SEP; Yu IPL; Huang CF; Morova T; Altıntaş UB; Giambartolomei C; Seo JH; Baca SC; Carneiro I; Emberly E; Pasaniuc B; Jerónimo C; Henrique R; Freedman ML; Wessels LFA; Lack NA; Bergman AM; Zwart W
Nat Commun; 2022 Nov; 13(1):7367. PubMed ID: 36450752
[TBL] [Abstract][Full Text] [Related]
15. Prostate Cancer Epigenetic Plasticity and Enhancer Heterogeneity: Molecular Causes, Consequences and Clinical Implications.
Kneppers J; Bergman AM; Zwart W
Adv Exp Med Biol; 2022; 1390():255-275. PubMed ID: 36107324
[TBL] [Abstract][Full Text] [Related]
16. Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer.
Lv S; Wu Z; Luo M; Zhang Y; Zhang J; Pascal LE; Wang Z; Wei Q
Cell Death Dis; 2022 Sep; 13(9):754. PubMed ID: 36050295
[TBL] [Abstract][Full Text] [Related]
17. FOXA1 in prostate cancer.
Dong HY; Ding L; Zhou TR; Yan T; Li J; Liang C
Asian J Androl; 2023; 25(3):287-295. PubMed ID: 36018068
[TBL] [Abstract][Full Text] [Related]
18. FOXA2 suppresses endometrial carcinogenesis and epithelial-mesenchymal transition by regulating enhancer activity.
Sahoo SS; Ramanand SG; Gao Y; Abbas A; Kumar A; Cuevas IC; Li HD; Aguilar M; Xing C; Mani RS; Castrillon DH
J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35703180
[TBL] [Abstract][Full Text] [Related]
19. Detection of disease-causing mutations in prostate cancer by NGS sequencing.
Mangolini A; Rocca C; Bassi C; Ippolito C; Negrini M; Dell'Atti L; Lanza G; Gafà R; Bianchi N; Pinton P; Aguiari G
Cell Biol Int; 2022 Jul; 46(7):1047-1061. PubMed ID: 35347810
[TBL] [Abstract][Full Text] [Related]
20. RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition.
Han W; Liu M; Han D; Li M; Toure AA; Wang Z; Besschetnova A; Patalano S; Macoska JA; Gao S; He HH; Cai C
Oncogene; 2022 Feb; 41(6):852-864. PubMed ID: 34975152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
